Zobrazeno 51 - 60
of 128
pro vyhledávání: '"Norio Ohmagari"'
Autor:
Michiyo Suzuki, Kayoko Hayakawa, Yusuke Asai, Nobuaki Matsunaga, Mari Terada, Hiroshi Ohtsu, Ako Toyoda, Jin Takasaki, Masayuki Hojo, Yasuaki Yanagawa, Sho Saito, Kei Yamamoto, Satoshi Ide, Yutaro Akiyama, Tetsuya Suzuki, Ataru Moriya, Kazuhisa Mezaki, Norio Ohmagari
Publikováno v:
Japanese journal of infectious diseases. 75(4)
The detection of other pathogens in patients with hospitalized coronavirus disease (COVID-19) are not frequent. Considering that data from Japan are limited, we conducted an observational study including patients with hospitalized COVID-19 at the Nat
Autor:
Harutaka Katano, Takato Nakamoto, Naoto Nunose, Isao Kondo, Daisuke Katagiri, Tadaki Suzuki, Ayako Okuhama, Takashi Fukaya, Noriko Kinoshita, Norio Ohmagari, Kohei Kanda, Fumihiko Hinoshita, Masahiro Ishikane
Publikováno v:
Emerging Infectious Diseases, Vol 26, Iss 11, Pp 2757-2760 (2020)
Emerging Infectious Diseases
Emerging Infectious Diseases
We report detection of severe acute respiratory syndrome coronavirus 2 RNA in hemodialysis effluent from a patient in Japan with coronavirus disease and prolonged inflammation. Healthcare workers should observe strict standard and contact precautions
Autor:
Sho Saito, Shinya Tsuzuki, Naoki Fujii, Nobuaki Matsunaga, Norio Ohmagari, Kayoko Hayakawa, Junko Terada-Hirashima, Kumiko Suzuki, Mio Endo, Taro Shibata, Yusuke Asai, Wataru Sugiura, Hiroshi Ohtsu, Ayako Mikami, Michiyo Suzuki, Mari Terada, Kazuo Izumi, Setsuko Suzuki, Masashi Kondo, Ako Toyoda, Yukari Uemura
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical infectious diseases
Clinical infectious diseases
Background There is limited understanding of the characteristics of patients with coronavirus disease 2019 (COVID-19) requiring hospitalization in Japan. Methods This study included 2638 cases enrolled from 227 healthcare facilities that participated
Autor:
Ryuta, Uraki, Maki, Kiso, Shun, Iida, Masaki, Imai, Emi, Takashita, Makoto, Kuroda, Peter J, Halfmann, Samantha, Loeber, Tadashi, Maemura, Seiya, Yamayoshi, Seiichiro, Fujisaki, Zhongde, Wang, Mutsumi, Ito, Michiko, Ujie, Kiyoko, Iwatsuki-Horimoto, Yuri, Furusawa, Ryan, Wright, Zhenlu, Chong, Seiya, Ozono, Atsuhiro, Yasuhara, Hiroshi, Ueki, Yuko, Sakai-Tagawa, Rong, Li, Yanan, Liu, Deanna, Larson, Michiko, Koga, Takeya, Tsutsumi, Eisuke, Adachi, Makoto, Saito, Shinya, Yamamoto, Masao, Hagihara, Keiko, Mitamura, Tetsuro, Sato, Masayuki, Hojo, Shin-Ichiro, Hattori, Kenji, Maeda, Riccardo, Valdez, Moe, Okuda, Jurika, Murakami, Calvin, Duong, Sucheta, Godbole, Daniel C, Douek, Ken, Maeda, Shinji, Watanabe, Aubree, Gordon, Norio, Ohmagari, Hiroshi, Yotsuyanagi, Michael S, Diamond, Hideki, Hasegawa, Hiroaki, Mitsuya, Tadaki, Suzuki, Lauren, Warsinske
Publikováno v:
Nature. 607(7917)
The recent emergence of SARS-CoV-2 Omicron (B.1.1.529 lineage) variants possessing numerous mutations has raised concerns of decreased effectiveness of current vaccines, therapeutic monoclonal antibodies and antiviral drugs for COVID-19 against these
Sex-associated differences between BMI and SARS-CoV-2 antibody titers following the BNT162b2 vaccine
Autor:
Shohei Yamamoto, Tetsuya Mizoue, Akihito Tanaka, Yusuke Oshiro, Natsumi Inamura, Maki Konishi, Mitsuru Ozeki, Kengo Miyo, Wataru Sugiura, Haruhito Sugiyama, Norio Ohmagari
Publikováno v:
Obesity (Silver Spring, Md.). 30(5)
This study investigated the sex-associated difference in the impact of obesity on antibody response to a COVID-19 vaccine.This study included 2,435 health care workers who received two doses of the BioNTech, Pfizer (BNT162b2) vaccine and participated
Autor:
Yusuke Miyazato, Kei Yamamoto, Yuichiro Nakaya, Shinichiro Morioka, Junko S. Takeuchi, Yuki Takamatsu, Kenji Maeda, Moto Kimura, Wataru Sugiura, Hiroaki Mitsuya, Masao Yano, Norio Ohmagari
Publikováno v:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 28(7)
Management of COVID-19 patients with humoral immunodeficiency is challenging. We describe a woman with COVID-19 with multiple relapses due to anti-CD20 monoclonal antibody treatment. She was successfully treated with casirivimab/imdevimab and confirm
Autor:
Yukio Hiroi, Hiroshi Ohtsu, Yukari Uemura, Kayoko Hayakawa, Yusuke Asai, Satoshi Kutsuna, Mari Terada, Wataru Sugiura, Norio Ohmagari
Publikováno v:
Circulation journal : official journal of the Japanese Circulation Society. 86(3)
Cardiovascular complications of coronavirus disease 2019 (COVID-19) are critical for prognosis but have not been elucidated in Japan.Methods and Results:The COVID-19 Registry Japan, which included data from 19,853 individuals at the end of 2020, was
Autor:
Emi Takashita, Noriko Kinoshita, Seiya Yamayoshi, Yuko Sakai-Tagawa, Seiichiro Fujisaki, Mutsumi Ito, Kiyoko Iwatsuki-Horimoto, Shiho Chiba, Peter Halfmann, Hiroyuki Nagai, Makoto Saito, Eisuke Adachi, David Sullivan, Andrew Pekosz, Shinji Watanabe, Kenji Maeda, Masaki Imai, Hiroshi Yotsuyanagi, Hiroaki Mitsuya, Norio Ohmagari, Makoto Takeda, Hideki Hasegawa, Yoshihiro Kawaoka
Publikováno v:
The New England journal of medicine. 386(10)
Autor:
Yusuke Miyazato, Shinya Tsuzuki, Shinichiro Morioka, Mari Terada, Satoshi Kutsuna, Sho Saito, Yumiko Shimanishi, Kozue Takahashi, Mio Sanada, Masako Akashi, Chika Kuge, Yasuyo Osanai, Keiko Tanaka, Michiyo Suzuki, Kayoko Hayakawa, Norio Ohmagari
Publikováno v:
Journal of infection and chemotherapy
Journal of Infection and Chemotherapy
Journal of Infection and Chemotherapy
Introduction: The post-COVID condition has become a social concern. Although the patient characteristics associated with the development of this condition are partially known, those associated with its persistence have not been identified.Methods: We
Publikováno v:
Epidemiology and Infection. 150
The risk factors specific to the elderly population for severe coronavirus disease 2019 (COVID-19) caused by the Omicron variant of concern (VOC) are not yet clear. We performed an exploratory analysis using logistic regression to identify risk facto